Click for best price
Squamous NonSmall Cell Lung Cancer Therapeutics Market Size, Share 2024
The global Squamous Non-Small Cell Lung Cancer Therapeutics market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period.
Report Overview
This report provides a deep insight into the global Squamous Non-Small Cell Lung Cancer Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Squamous Non-Small Cell Lung Cancer Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Squamous Non-Small Cell Lung Cancer Therapeutics market in any manner.
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Ascenta Therapeutics, Inc.
- AstraZeneca Plc
- AVEO Pharmaceuticals, Inc.
- Bayer AG
- BIND Therapeutics, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Five Prime Therapeutics, Inc.
- Genentech, Inc.
- Incyte Corporation
- Johnson & Johnson
- MacroGenics, Inc.
- Novartis AG
- Oncogenex Pharmaceuticals, Inc.
- PsiOxus Therapeutics Limited
Market Segmentation (by Type)
- BMS-906024
- Buparlisib Hydrochloride
- FP-1039
- Ipilimumab
- JNJ-42756493
- Lenvatinib
- Others
Market Segmentation (by Application)
- Research Center
- Hospital
- Clinic
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Squamous Non-Small Cell Lung Cancer Therapeutics Market
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porters five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Squamous Non-Small Cell Lung Cancer Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Research Report 2024(Status and Outlook) |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
151 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Squamous Non-Small Cell Lung Cancer Therapeutics
1.2 Key Market Segments
1.2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Type
1.2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Overview
2.1 Global Market Overview
2.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Competitive Landscape
3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Squamous Non-Small Cell Lung Cancer Therapeutics Sales Sites, Area Served, Product Type
3.6 Squamous Non-Small Cell Lung Cancer Therapeutics Market Competitive Situation and Trends
3.6.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Squamous Non-Small Cell Lung Cancer Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Chain Analysis
4.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Squamous Non-Small Cell Lung Cancer Therapeutics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Squamous Non-Small Cell Lung Cancer Therapeutics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Price by Type (2019-2024)
7 Squamous Non-Small Cell Lung Cancer Therapeutics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Sales by Application (2019-2024)
7.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Growth Rate by Application (2019-2024)
8 Squamous Non-Small Cell Lung Cancer Therapeutics Market Segmentation by Region
8.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Region
8.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Region
8.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Ascenta Therapeutics, Inc.
9.1.1 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.1.2 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.1.4 Ascenta Therapeutics, Inc. Business Overview
9.1.5 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
9.1.6 Ascenta Therapeutics, Inc. Recent Developments
9.2 AstraZeneca Plc
9.2.1 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.2.2 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.2.4 AstraZeneca Plc Business Overview
9.2.5 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
9.2.6 AstraZeneca Plc Recent Developments
9.3 AVEO Pharmaceuticals, Inc.
9.3.1 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.3.2 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
9.3.5 AVEO Pharmaceuticals, Inc. Business Overview
9.3.6 AVEO Pharmaceuticals, Inc. Recent Developments
9.4 Bayer AG
9.4.1 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.4.2 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.4.4 Bayer AG Business Overview
9.4.5 Bayer AG Recent Developments
9.5 BIND Therapeutics, Inc.
9.5.1 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.5.2 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.5.4 BIND Therapeutics, Inc. Business Overview
9.5.5 BIND Therapeutics, Inc. Recent Developments
9.6 Boehringer Ingelheim GmbH
9.6.1 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.6.2 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.6.4 Boehringer Ingelheim GmbH Business Overview
9.6.5 Boehringer Ingelheim GmbH Recent Developments
9.7 Bristol-Myers Squibb Company
9.7.1 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.7.2 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.7.4 Bristol-Myers Squibb Company Business Overview
9.7.5 Bristol-Myers Squibb Company Recent Developments
9.8 Eli Lilly and Company
9.8.1 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.8.2 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.8.4 Eli Lilly and Company Business Overview
9.8.5 Eli Lilly and Company Recent Developments
9.9 F. Hoffmann-La Roche Ltd.
9.9.1 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.9.2 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.9.4 F. Hoffmann-La Roche Ltd. Business Overview
9.9.5 F. Hoffmann-La Roche Ltd. Recent Developments
9.10 Five Prime Therapeutics, Inc.
9.10.1 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.10.2 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.10.4 Five Prime Therapeutics, Inc. Business Overview
9.10.5 Five Prime Therapeutics, Inc. Recent Developments
9.11 Genentech, Inc.
9.11.1 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.11.2 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.11.4 Genentech, Inc. Business Overview
9.11.5 Genentech, Inc. Recent Developments
9.12 Incyte Corporation
9.12.1 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.12.2 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.12.4 Incyte Corporation Business Overview
9.12.5 Incyte Corporation Recent Developments
9.13 Johnson and Johnson
9.13.1 Johnson and Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.13.2 Johnson and Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.13.3 Johnson and Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.13.4 Johnson and Johnson Business Overview
9.13.5 Johnson and Johnson Recent Developments
9.14 MacroGenics, Inc.
9.14.1 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.14.2 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.14.4 MacroGenics, Inc. Business Overview
9.14.5 MacroGenics, Inc. Recent Developments
9.15 Novartis AG
9.15.1 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.15.2 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.15.4 Novartis AG Business Overview
9.15.5 Novartis AG Recent Developments
9.16 Oncogenex Pharmaceuticals, Inc.
9.16.1 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.16.2 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.16.4 Oncogenex Pharmaceuticals, Inc. Business Overview
9.16.5 Oncogenex Pharmaceuticals, Inc. Recent Developments
9.17 PsiOxus Therapeutics Limited
9.17.1 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
9.17.2 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
9.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product Market Performance
9.17.4 PsiOxus Therapeutics Limited Business Overview
9.17.5 PsiOxus Therapeutics Limited Recent Developments
10 Squamous Non-Small Cell Lung Cancer Therapeutics Market Forecast by Region
10.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast
10.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country
10.2.3 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Region
10.2.4 South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Squamous Non-Small Cell Lung Cancer Therapeutics by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Squamous Non-Small Cell Lung Cancer Therapeutics by Type (2025-2030)
11.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Squamous Non-Small Cell Lung Cancer Therapeutics by Type (2025-2030)
11.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Forecast by Application (2025-2030)
11.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) Forecast by Application
11.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Comparison by Region (M USD)
Table 5. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2022)
Table 10. Global Market Squamous Non-Small Cell Lung Cancer Therapeutics Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Squamous Non-Small Cell Lung Cancer Therapeutics Sales Sites and Area Served
Table 12. Manufacturers Squamous Non-Small Cell Lung Cancer Therapeutics Product Type
Table 13. Global Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Squamous Non-Small Cell Lung Cancer Therapeutics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges
Table 22. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Type (K Units)
Table 23. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (M USD)
Table 24. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) by Type (2019-2024)
Table 25. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Type (2019-2024)
Table 26. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (M USD) by Type (2019-2024)
Table 27. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Share by Type (2019-2024)
Table 28. Global Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) by Type (2019-2024)
Table 29. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) by Application
Table 30. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application
Table 31. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Application (2019-2024) & (K Units)
Table 32. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Application (2019-2024)
Table 33. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Application (2019-2024) & (M USD)
Table 34. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2019-2024)
Table 35. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Growth Rate by Application (2019-2024)
Table 36. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Region (2019-2024) & (K Units)
Table 37. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Region (2019-2024)
Table 38. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Country (2019-2024) & (K Units)
Table 39. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Region (2019-2024) & (K Units)
Table 41. South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Region (2019-2024) & (K Units)
Table 43. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 44. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 45. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Ascenta Therapeutics, Inc. Business Overview
Table 47. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 48. Ascenta Therapeutics, Inc. Recent Developments
Table 49. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 50. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 51. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. AstraZeneca Plc Business Overview
Table 53. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 54. AstraZeneca Plc Recent Developments
Table 55. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 56. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 57. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics SWOT Analysis
Table 59. AVEO Pharmaceuticals, Inc. Business Overview
Table 60. AVEO Pharmaceuticals, Inc. Recent Developments
Table 61. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 62. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 63. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Bayer AG Business Overview
Table 65. Bayer AG Recent Developments
Table 66. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 67. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 68. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. BIND Therapeutics, Inc. Business Overview
Table 70. BIND Therapeutics, Inc. Recent Developments
Table 71. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 72. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 73. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Boehringer Ingelheim GmbH Business Overview
Table 75. Boehringer Ingelheim GmbH Recent Developments
Table 76. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 77. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 78. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Bristol-Myers Squibb Company Business Overview
Table 80. Bristol-Myers Squibb Company Recent Developments
Table 81. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 82. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 83. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Eli Lilly and Company Business Overview
Table 85. Eli Lilly and Company Recent Developments
Table 86. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 87. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 88. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. F. Hoffmann-La Roche Ltd. Business Overview
Table 90. F. Hoffmann-La Roche Ltd. Recent Developments
Table 91. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 92. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 93. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Five Prime Therapeutics, Inc. Business Overview
Table 95. Five Prime Therapeutics, Inc. Recent Developments
Table 96. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 97. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 98. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Genentech, Inc. Business Overview
Table 100. Genentech, Inc. Recent Developments
Table 101. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 102. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 103. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Incyte Corporation Business Overview
Table 105. Incyte Corporation Recent Developments
Table 106. Johnson and Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 107. Johnson and Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 108. Johnson and Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Johnson and Johnson Business Overview
Table 110. Johnson and Johnson Recent Developments
Table 111. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 112. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 113. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. MacroGenics, Inc. Business Overview
Table 115. MacroGenics, Inc. Recent Developments
Table 116. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 117. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 118. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Novartis AG Business Overview
Table 120. Novartis AG Recent Developments
Table 121. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 122. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 123. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Oncogenex Pharmaceuticals, Inc. Business Overview
Table 125. Oncogenex Pharmaceuticals, Inc. Recent Developments
Table 126. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Basic Information
Table 127. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product Overview
Table 128. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. PsiOxus Therapeutics Limited Business Overview
Table 130. PsiOxus Therapeutics Limited Recent Developments
Table 131. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Region (2025-2030) & (K Units)
Table 132. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 133. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 134. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 135. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 136. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 137. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Region (2025-2030) & (K Units)
Table 138. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 139. South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 140. South America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 141. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Consumption Forecast by Country (2025-2030) & (Units)
Table 142. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 143. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Type (2025-2030) & (K Units)
Table 144. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Type (2025-2030) & (M USD)
Table 145. Global Squamous Non-Small Cell Lung Cancer Therapeutics Price Forecast by Type (2025-2030) & (USD/Unit)
Table 146. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) Forecast by Application (2025-2030)
Table 147. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Squamous Non-Small Cell Lung Cancer Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (M USD), 2019-2030
Figure 5. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (M USD) (2019-2030)
Figure 6. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (M USD)
Figure 11. Squamous Non-Small Cell Lung Cancer Therapeutics Sales Share by Manufacturers in 2023
Figure 12. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Manufacturers in 2023
Figure 13. Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Squamous Non-Small Cell Lung Cancer Therapeutics Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type
Figure 18. Sales Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics by Type (2019-2024)
Figure 19. Sales Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics by Type in 2023
Figure 20. Market Size Share of Squamous Non-Small Cell Lung Cancer Therapeutics by Type (2019-2024)
Figure 21. Market Size Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application
Figure 24. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Application (2019-2024)
Figure 25. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Application in 2023
Figure 26. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2019-2024)
Figure 27. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application in 2023
Figure 28. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Region (2019-2024)
Figure 30. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Country in 2023
Figure 32. U.S. Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Country in 2023
Figure 37. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Region in 2023
Figure 44. China Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (K Units)
Figure 50. South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Country in 2023
Figure 51. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share Forecast by Type (2025-2030)
Figure 65. Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Application (2025-2030)
Figure 66. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share Forecast by Application (2025-2030)
